Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Active not recruiting 6Completed 3Recruiting 2Withdrawn 1Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2Lymphoid 1

Conditions

Melanoma 4Thyroid Carcinoma, Anaplastic 3Neoplasms 3Glioma 3Recurrence 2Neurofibromatosis 1 2Neoplasm Metastasis 2Multiple Myeloma 2Carcinoma, Non-Small-Cell Lung 2Astrocytoma 2Thyroid Neoplasms 1Solid Tumor Cancer 1Solid Tumor 1Skin Neoplasms 1Sexual Dysfunction, Physiological 1Refractory Differentiated Thyroid Gland Carcinoma 1Rare Malignant Neoplasm 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Osteosarcoma 1Oligodendroglioma 1Neurofibroma, Plexiform 1Neurocytoma 1Neuroblastoma 1Meningioma 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Locally Advanced Thyroid Gland Carcinoma 1Leukemia, Myelomonocytic, Juvenile 1

Interventions

Dexamethasone 87daratumumab 49Lenalidomide 49pomalidomide 33Bortezomib 32Cyclophosphamide 31carfilzomib 25Calcium Dobesilate 21talquetamab 19fludarabine 18isatuximab 16iberdomide 16Magnetic Resonance Spectroscopy 16Specimen Handling 15Biopsy 14selinexor 12Melphalan 11belantamab mafodotin 10dexamethasone acetate 9dexamethasone 21-phosphate 8elotuzumab 7auricularum 7venetoclax 6tocilizumab 5fludarabine phosphate 5X-Rays 5Blood Specimen Collection 5ruxolitinib 4Methylprednisolone 4Injections 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Multiple Myeloma × trametinib × Clear all
NCT02693535 2026-05-29

TAPUR

American Society of Clinical Oncology

Phase 2 Recruiting
4,200 enrolled
LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms

NCT05372354 2025-09-05

A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma

Bristol-Myers Squibb

Phase 1/2 Recruiting
260 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡